Dr. Torsten Matthias accepts the 2026 German Medical Award on behalf of MODAG

WENDELSHEIM, 18 November 2026

- MODAG GmbH, based in Wendelsheim (Alzey-Worms district), has received the 2026 German Medical Award in the “Medical Technology & Life Science” category. CEO and Managing Director Dr. Torsten Matthias accepted the award on November 12 in Düsseldorf.

- The award recognized MODAG’s work on active ingredients to combat pathological protein deposits in the brain, which are characteristic of Parkinson’s disease. With PD DETECT®, the company had already launched the world’s first CE-certified test for these deposits in cerebrospinal fluid in March.

- Dr. Torsten Matthias commented: “For our team in Wendelsheim, this recognition is both an honor and an incentive to continue advancing science.”

- In October, MODAG had already won the CPHI Pharma Award 2026 in Milan.

About MODAG
MODAG GmbH is a privately held German biotechnology company focused on developing disease-modifying therapeutics and diagnostics for neurodegenerative diseases. Based on a broad portfolio of patented compounds, MODAG develops innovative oligomer modulators and diagnostic tools that target the causes of synucleinopathies such as Parkinson’s disease and MSA, as well as other neurodegenerative diseases such as Alzheimer’s.

Contact
Nils Wigger
Email: n.wigger@dunkelblau360.com
Mobile: +49 160 3238 942